Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.
1. A gel composition, comprising:
a) a therapeutically effective amount of i) morselized placental amniotic membrane and ii) morselized umbilical cord; and
b) a pharmaceutically-acceptable excipient;
wherein water has not been substantially removed from the morselized amniotic membrane or from the morselized umbilical cord; and
wherein the morselized placental amniotic membrane and the morselized umbilical cord have a particle size from about 0.3 mm to about 1 cm in length, width, and thickness.
2. The gel composition according to claim 1 , wherein the gel composition has reduced water content by weight percentage compared to the morselized placental amniotic membrane or the morselized umbilical cord before morselization.
3. The gel composition according to claim 1 , wherein the gel composition has a water content greater than 20% by weight percentage.
4. The gel composition according to claim 1 , wherein the gel composition is sterilized.
5. The gel composition according to claim 4 , wherein the gel composition is sterilized by gamma (γ) radiation.
6. The gel composition according claim 1 , wherein the morselized placental amniotic membrane and the morselized umbilical cord have a biological activity that is substantially preserved for at least 15 days after initial procurement of the morselized placental amniotic membrane and the morselized umbilical cord.
7. The gel composition according to claim 1 , wherein the composition is anti-inflammatory, anti-scarring, anti-angiogenic, anti-adhesion, promotes wound healing, or a combination thereof.
8. The gel composition according to claim 1 , wherein the morselized placental amniotic membrane and the morselized umbilical cord are substantially free of red blood cells.
9. The gel composition according to claim 1 , wherein the morselized placental amniotic membrane substantially free of chorion.
10. The gel composition according to claim 1 , wherein the morselized placental amniotic membrane further comprises chorion.
11. The gel composition according to claim 1 , wherein the gel composition further comprises amniotic fluid.
12. The gel composition according to claim 1 , further comprising at least one pharmaceutically acceptable carrier or diluent selected from the group consisting of: acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, polyvinylpyrrollidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphotidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose, dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose, compressible sugar, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; sodium chloride, inositol, and bentonite.
13. The gel composition according to claim 1 , wherein the morselized placental amniotic membrane, morselized umbilical cord or combination thereof is a homogenate.
14. The gel composition according to claim 1 , wherein the morselized placental amniotic membrane and the morselized umbilical cord are homogenized.
15. A method of repairing damaged nerve tissue in an individual in need thereof comprising administering to damaged nerve tissue a therapeutically effective amount of the gel composition according to claim 1 .
16. An apparatus comprising: (a) an inert support, and (b) a gel composition of claim 1 disposed on the inert support.
17. The apparatus of claim 16 , wherein the inert support is a mesh sheet with an average pore size of about 0.2 mm to about 0.9 cm.
18. The apparatus of claim 16 , wherein the inert support comprises a material selected from the group consisting of: collagen; hydrogels; keratin; hydrophilic polyurethane; polyethylene glycols; poly(lactic-co-glycolic acids); and hydrocolloids.